Wassim W Labaki1, Meng Xia2, Susan Murray2, Charles R Hatt3, Abdullah Al-Abcha4, Michael C Ferrera1, Catherine A Meldrum1, Lauren A Keith3, Craig J Galbán5, Douglas A Arenberg1, Jeffrey L Curtis6, Fernando J Martinez7, Ella A Kazerooni5, MeiLan K Han8. 1. Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI. 2. Department of Biostatistics, University of Michigan, Ann Arbor, MI. 3. Imbio LLC, Minneapolis, MN. 4. Department of Internal Medicine, Michigan State University, East Lansing, MI. 5. Department of Radiology, University of Michigan, Ann Arbor, MI. 6. Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI; Medical Service, VA Ann Arbor Healthcare System, Ann Arbor, MI. 7. Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI; Division of Pulmonary and Critical Care Medicine, Weill Cornell Medical College, New York, NY. 8. Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI. Electronic address: mrking@med.umich.edu.
Abstract
BACKGROUND: Lung cancer risk prediction models do not routinely incorporate imaging metrics available on low-dose CT (LDCT) imaging of the chest ordered for lung cancer screening. RESEARCH QUESTION: What is the association between quantitative emphysema measured on LDCT imaging and lung cancer incidence and mortality, all-cause mortality, and airflow obstruction in individuals who currently or formerly smoked and are undergoing lung cancer screening? STUDY DESIGN AND METHODS: In 7,262 participants in the CT arm of the National Lung Screening Trial, percent low attenuation area (%LAA) was defined as the percentage of lung volume with voxels less than -950 Hounsfield units on the baseline examination. Multivariable Cox proportional hazards models, adjusting for competing risks where appropriate, were built to test for association between %LAA and lung cancer incidence, lung cancer mortality, and all-cause mortality with censoring at 6 years. In addition, multivariable logistic regression models were built to test the cross-sectional association between %LAA and airflow obstruction on spirometry, which was available in 2,700 participants. RESULTS: The median %LAA was 0.8% (interquartile range, 0.2%-2.7%). Every 1% increase in %LAA was independently associated with higher hazards of lung cancer incidence (hazard ratio [HR], 1.02; 95% CI, 1.01-1.03; P = .004), lung cancer mortality (HR, 1.02; 95% CI, 1.00-1.05; P = .045), and all-cause mortality (HR, 1.01; 95% CI, 1.00-1.03; P = .042). Among participants with spirometry, 892 had airflow obstruction. The likelihood of airflow obstruction increased with every 1% increase in %LAA (odds ratio, 1.07; 95% CI, 1.06-1.09; P < .001). A %LAA cutoff of 1% had the best discriminative accuracy for airflow obstruction in participants aged > 65 years. INTERPRETATION: Quantitative emphysema measured on LDCT imaging of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked and are undergoing lung cancer screening.
BACKGROUND: Lung cancer risk prediction models do not routinely incorporate imaging metrics available on low-dose CT (LDCT) imaging of the chest ordered for lung cancer screening. RESEARCH QUESTION: What is the association between quantitative emphysema measured on LDCT imaging and lung cancer incidence and mortality, all-cause mortality, and airflow obstruction in individuals who currently or formerly smoked and are undergoing lung cancer screening? STUDY DESIGN AND METHODS: In 7,262 participants in the CT arm of the National Lung Screening Trial, percent low attenuation area (%LAA) was defined as the percentage of lung volume with voxels less than -950 Hounsfield units on the baseline examination. Multivariable Cox proportional hazards models, adjusting for competing risks where appropriate, were built to test for association between %LAA and lung cancer incidence, lung cancer mortality, and all-cause mortality with censoring at 6 years. In addition, multivariable logistic regression models were built to test the cross-sectional association between %LAA and airflow obstruction on spirometry, which was available in 2,700 participants. RESULTS: The median %LAA was 0.8% (interquartile range, 0.2%-2.7%). Every 1% increase in %LAA was independently associated with higher hazards of lung cancer incidence (hazard ratio [HR], 1.02; 95% CI, 1.01-1.03; P = .004), lung cancer mortality (HR, 1.02; 95% CI, 1.00-1.05; P = .045), and all-cause mortality (HR, 1.01; 95% CI, 1.00-1.03; P = .042). Among participants with spirometry, 892 had airflow obstruction. The likelihood of airflow obstruction increased with every 1% increase in %LAA (odds ratio, 1.07; 95% CI, 1.06-1.09; P < .001). A %LAA cutoff of 1% had the best discriminative accuracy for airflow obstruction in participants aged > 65 years. INTERPRETATION: Quantitative emphysema measured on LDCT imaging of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked and are undergoing lung cancer screening.
Authors: Denise R Aberle; Christine D Berg; William C Black; Timothy R Church; Richard M Fagerstrom; Barbara Galen; Ilana F Gareen; Constantine Gatsonis; Jonathan Goldin; John K Gohagan; Bruce Hillman; Carl Jaffe; Barnett S Kramer; David Lynch; Pamela M Marcus; Mitchell Schnall; Daniel C Sullivan; Dorothy Sullivan; Carl J Zylak Journal: Radiology Date: 2010-11-02 Impact factor: 11.105
Authors: Juan P de-Torres; Juan P Wisnivesky; Gorka Bastarrika; David O Wilson; Bartolome R Celli; Javier J Zulueta Journal: Ann Am Thorac Soc Date: 2019-05
Authors: Onno M Mets; Constantinus F M Buckens; Pieter Zanen; Ivana Isgum; Bram van Ginneken; Mathias Prokop; Hester A Gietema; Jan-Willem J Lammers; Rozemarijn Vliegenthart; Matthijs Oudkerk; Rob J van Klaveren; Harry J de Koning; Willem P Th M Mali; Pim A de Jong Journal: JAMA Date: 2011-10-26 Impact factor: 56.272
Authors: Patrick C Yong; Keith Sigel; Juan Pablo de-Torres; Grace Mhango; Minal Kale; Chung Yin Kong; Javier J Zulueta; David Wilson; Stacey-Ann Whittaker Brown; Christopher Slatore; Juan Wisnivesky Journal: Thorax Date: 2019-02-05 Impact factor: 9.139
Authors: Rachel Denholm; Joachim Schüz; Kurt Straif; Isabelle Stücker; Karl-Heinz Jöckel; Darren R Brenner; Sara De Matteis; Paolo Boffetta; Florence Guida; Irene Brüske; Heinz-Erich Wichmann; Maria Teresa Landi; Neil Caporaso; Jack Siemiatycki; Wolfgang Ahrens; Hermann Pohlabeln; David Zaridze; John K Field; John McLaughlin; Paul Demers; Neonila Szeszenia-Dabrowska; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Rodica Stanescu Dumitru; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Benjamin Kendzia; Susan Peters; Thomas Behrens; Roel Vermeulen; Thomas Brüning; Hans Kromhout; Ann C Olsson Journal: Am J Respir Crit Care Med Date: 2014-09-01 Impact factor: 21.405
Authors: Mamta Ruparel; Samantha L Quaife; Jennifer L Dickson; Carolyn Horst; Stephen Burke; Magali Taylor; Asia Ahmed; Penny Shaw; May-Jan Soo; Arjun Nair; Anand Devaraj; Emma Louise O'Dowd; Angshu Bhowmik; Neal Navani; Karen Sennett; Stephen W Duffy; David R Baldwin; Reecha Sofat; Riyaz S Patel; Aroon Hingorani; Sam M Janes Journal: Thorax Date: 2019-09-26 Impact factor: 9.102
Authors: Asha Bonney; Reem Malouf; Corynne Marchal; David Manners; Kwun M Fong; Henry M Marshall; Louis B Irving; Renée Manser Journal: Cochrane Database Syst Rev Date: 2022-08-03
Authors: Jae-Kwang Lim; Byunggeon Park; Jongmin Park; Keum-Ju Choi; Chi-Young Jung; Young Hwan Kim; Jin Young Kim; Sungjun Moon; Yong Hoon Lee; Jaehee Lee Journal: Int J Gen Med Date: 2021-07-12